________________________________________________________________________________________________________________________________

(C) Wolf G Kroner 2009 - Mark Charles FishmanPreparing for Another Level of Innovation

February 2009. How does Novartis use its stem cell patents? Dr Mark Fishman, President of the Novartis Institutes for BioMedical Research (NIBR) and Member of the Executive Committee of Novartis, comments his company’s strategy including technology acquisitions in the field.

 

 

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 1 page

Full Company License enquire here

Back to section

Related Editorial Articles

Leroy Hood: Thinking Further about Stem Cells

Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan Knowles, Former Member of the Roche Executive Committee and Head of Group Research Leveraging different methods and technologies – clarifying the concept of personalised medicine

Pfizer Regenerative Medicine (Neusentis): It really started last year…
Ruth McKernan, global CSO of Pfizer’s Regenerative Medicine Unit (today Neusentis) addresses basic and practical issues in pharmaceutical research on stem cells

Patenting Stem Cells – Behind the Front Stages
The patentability of stem cells is of continuing debate. The article outlines the legal approach to stem cells as it informs solving juridical problems.

Adhering to Values Pays Off
Novartis continues to expand the biotech therapeutics pipeline / Focus on emerging markets

Novartis counter-moves Vetoquinol, Virbac, and others in animal health
Editor's Note PR Okapi Life Sciences